Chronological effects of rifampicin discontinuation on cytochrome p450 activity in healthy Japanese Volunteers, using the cocktail method

Clinical Pharmacology and Therapeutics

Volumn 94, Issue 6, 2013, Pages 702-708

  Inui, N ^a   Akamatsu, T ^a   Uchida, S ^b   Tanaka, S ^b   Namiki, N ^b   Karayama, M ^a   Chida, K ^a   Watanabe, H ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; 5' HYDROXYOMEPRAZOLE; ALPHA HYDROXYMIDAZOLAM; CAFFEINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; DEXTROMETHORPHAN; DEXTRORPHAN; LOSARTAN; MIDAZOLAM; MIDAZOLAM MALEATE; NU LOTAN; OMEPRAZOLE; OMEPRAZOLE DERIVATIVE; PARAXANTHINE; RIFAMPICIN; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ANTIBIOTICS, ANTITUBERCULAR; ASIAN CONTINENTAL ANCESTRY GROUP; CAFFEINE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; HUMANS; IMIDAZOLES; LOSARTAN; MALE; MIDAZOLAM; OMEPRAZOLE; RIFAMPIN; TETRAZOLES; THEOPHYLLINE; TIME FACTORS; WITHHOLDING TREATMENT;

EID: 84887992191     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.167     Document Type: Article

References (31)

1. Blumberg, H.M. et al.; American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167, 603-662 (2003).
2. Christensen, M. et al. The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin. Pharmacol. Ther. 73, 517-528 (2003). (Pubitemid 37249122)
3. Gorski, J.C. et al. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin. Pharmacol. Ther. 74, 275-287 (2003). (Pubitemid 37083103)
4. Graham, D.J. et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292, 2585-2590 (2004). (Pubitemid 39577514)
5. Malcolm, R. & Tozer, T.N. Clinical Pharmacokinetics: InConcepts and Application. (eds. Malcolm, R. & Tozer, T.N.) 119-183 (Williams & Wilkins, Baltimore, MD, 1995).
6. Zhang, Q.Y., Dunbar, D., Ostrowska, A., Zeisloft, S., Yang, J. & Kaminsky, L.S. Characterization of human small intestinal cytochromes P-450. Drug Metab. Dispos. 27, 804-809 (1999). (Pubitemid 29297778)
7. Guengerich, F.P. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol. 39, 1-17 (1999). (Pubitemid 29222549)
8. Fromm, M.F., Busse, D., Kroemer, H.K. & Eichelbaum, M. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 24, 796-801 (1996). (Pubitemid 26334275)
9. Backman, J.T., Kivistö, K.T., Olkkola, K.T. & Neuvonen, P.J. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur. J. Clin. Pharmacol. 54, 53-58 (1998). (Pubitemid 28189400)
10. Niemi, M., Backman, J.T., Fromm, M.F., Neuvonen, P.J. & Kivistö, K.T. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin. Pharmacokinet. 42, 819-850 (2003). (Pubitemid 36995083)
11. Ryu, J.Y. et al. Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo. Clin. Pharmacol. Ther. 82, 531-540 (2007). (Pubitemid 47622519)
12. Frye, R.F., Matzke, G.R., Adedoyin, A., Porter, J.A. & Branch, R.A. Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes. Clin. Pharmacol. Ther. 62, 365-376 (1997). (Pubitemid 27475220)
13. Chainuvati, S. et al. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail". Clin. Pharmacol. Ther. 74, 437-447 (2003). (Pubitemid 37357722)
14. Christians, U., Jacobsen, W. & Floren, L.C. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol. Ther. 80, 1-34 (1998). (Pubitemid 28498199)
15. Streetman, D.S., Bertino, J.S. Jr & Nafziger, A.N. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10, 187-216 (2000). (Pubitemid 30242736)
16. Wienkers, L.C. & Heath, T.G. Predicting in vivo drug interactions from in vitro drug discovery data. Nat. Rev. Drug Discov. 4, 825-833 (2005). (Pubitemid 41553963)
17. Guengerich, F.P. In vitro techniques for studying drug metabolism. J. Pharmacokinet. Biopharm. 24, 521-533 (1996). (Pubitemid 27156936)
18. Misaka, S. et al. Pharmacokinetics and pharmacodynamics of low doses of midazolam administered intravenously and orally to healthy volunteers. Clin. Exp. Pharmacol. Physiol. 37, 290-295 (2010).
19. Kanebratt, K.P. et al. Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol. Clin. Pharmacol. Ther. 84, 589-594 (2008).
20. Williamson, K.M., Patterson, J.H., McQueen, R.H., Adams, K.F. Jr & Pieper, J.A. Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. Clin. Pharmacol. Ther. 63, 316-323 (1998). (Pubitemid 28182229)
21. Vormfelde, S.V. et al. Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers. Clin. Pharmacol. Ther. 86, 54-61 (2009).
22. Neuvonen, P.J., Niemi, M. & Backman, J.T. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin. Pharmacol. Ther. 80, 565-581 (2006). (Pubitemid 44908269)
23. Imai, H. et al. The recovery time-course of CYP3A after induction by St John's wort administration. Br. J. Clin. Pharmacol. 65, 701-707 (2008). (Pubitemid 351535099)
24. Faber, M.S. & Fuhr, U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin. Pharmacol. Ther. 76, 178-184 (2004). (Pubitemid 39013407)
25. Greenblatt, D.J. et al. Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. Clin. Pharmacol. Ther. 74, 121-129 (2003). (Pubitemid 36951809)
26. Obach, R.S., Walsky, R.L. & Venkatakrishnan, K. Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab. Dispos. 35, 246-255 (2007). (Pubitemid 46148737)
27. Wang, Y.H., Jones, D.R. & Hall, S.D. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab. Dispos. 32, 259-266 (2004). (Pubitemid 38176944)
28. Yang, J. et al. Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr. Drug Metab. 9, 384-394 (2008).
29. Reitman, M.L. et al. Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design. Clin. Pharmacol. Ther. 89, 234-242 (2011).
30. Andersson, T., Regårdh, C.G., Lou, Y.C., Zhang, Y., Dahl, M.L. & Bertilsson, L. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 2, 25-31 (1992).
31. Kubota, T., Yamaura, Y., Ohkawa, N., Hara, H. & Chiba, K. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br. J. Clin. Pharmacol. 50, 31-34 (2000). (Pubitemid 30416968)